Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,08,025 Cr
Revenue (TTM)
₹34,682 Cr
Net Profit (TTM)
₹5,568 Cr
ROE
18.6 %
ROCE
23.3 %
P/E Ratio
19.4
P/B Ratio
2.9
Industry P/E
29.25
EV/EBITDA
11.7
Div. Yield
0.6 %
Debt to Equity
0.1
Book Value
₹445.7
EPS
₹66.7
Face value
1
Shares outstanding
834,653,295
CFO
₹34,519.20 Cr
EBITDA
₹44,523.80 Cr
Net Profit
₹28,197.80 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Dr. Reddy'S Labs
| 1.8 | 0.8 | 1.8 | 12.5 | 13.4 | 8.2 | 7.6 |
|
BSE Sensex
| -9.4 | -8.1 | -9.3 | 3.4 | 9.8 | 9.0 | 12.0 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Dr. Reddy'S Labs
| -7.1 | 19.3 | 36.8 | -13.6 | -6.4 | 80.8 | 10.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Dr. Reddy'S Labs
|
1,294.8 | 1,08,025.0 | 34,682.2 | 5,508.7 | 17.6 | 16 | 19.4 | 2.9 |
| 5,351.5 | 63,950.5 | 14,252.7 | 2,424.5 | 17.5 | 19 | 27 | 4.6 | |
| 1,269.0 | 73,703.7 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 21.1 | 2.1 | |
| 382.6 | 61,967.3 | 16,827.4 | 629.6 | 9.6 | -0.1 | 102.6 | 1.6 | |
| 1,268.5 | 1,02,442.8 | 28,351.1 | 4,544.7 | 18.8 | 14.8 | 22.5 | 3.0 | |
| 2,302.4 | 1,05,236.5 | 26,150.5 | 4,669.2 | 24.2 | 27 | 22.7 | 5.1 | |
| 2,103.1 | 86,793.0 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 48.8 | 5.5 | |
| 1,778.3 | 4,26,781.7 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 39.1 | 5.3 | |
| 4,289.3 | 1,45,252.3 | 12,742.0 | 2,272.0 | 26.3 | 28.8 | 63.9 | 16.0 | |
| 899.6 | 90,435.3 | 26,089.3 | 4,933.9 | 24.7 | 21 | 18.3 | 3.4 |
A hunt for quality large caps available cheap
3 min read•By Jugal Harpalani
2 min read•By Mohammed Ekramul Haque
3 min read•By Research Desk
Who wins in India: Value or Growth?
3 min read•By Kumar Shankar Roy
FIIs Vs DIIs: Different strokes
3 min read•By Kumar Shankar Roy
Grab top stocks quoting at a discount
2 min read•By Mohammed Ekramul Haque
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The... company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Read more
Incorporated
1984
Chairman
K Satish Reddy
Managing Director
GV Prasad
Group
Dr. Reddy's
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Dr. Reddy's Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Dr Reddy's Laboratories Ltd is ₹1,294.80 (NSE) and ₹1,294.25 (BSE) as of 18-Mar-2026 IST. Dr Reddy's Laboratories Ltd has given a return of 13.43% in the last 3 years.
The P/E ratio of Dr Reddy's Laboratories Ltd is 19.40 times as on 18-Mar-2026, a 34 discount to its peers’ median range of 29.25 times.
The P/B ratio of Dr Reddy's Laboratories Ltd is 2.90 times as on 18-Mar-2026, a 36 discount to its peers’ median range of 4.56 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
16.87
|
2.86
|
|
2024
|
3.68
|
3.65
|
|
2023
|
3.42
|
3.33
|
|
2022
|
32.83
|
3.76
|
|
2021
|
38.50
|
4.29
|
The 52-week high and low of Dr Reddy's Laboratories Ltd are Rs 1,379.70 and Rs 1,020.00 as of 19-Mar-2026.
Dr Reddy's Laboratories Ltd has a market capitalisation of ₹ 1,08,025 Cr as on 18-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Dr Reddy's Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹11.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.